We are live on ! Find out more
RXDX

Prometheus Biosciences, Inc. Common Stock
RXDX

Delisted

RXDX was delisted on the 15th of June, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of RXDX yet.

RXDX Hedge Fund Activity: Q3 2023 in Review

0 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q3 2023, worth a combined $0 — down 100% from $1.98M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RXDX and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was UBS AM, exiting entirely with an estimated $1.98M sold.

  • 0 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q3 2023, down from 2 in Q2 2023.
  • Funds reported $0 of Prometheus Biosciences, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of -2 holders.
  • The largest Prometheus Biosciences, Inc. Common Stock seller in Q3 2023 was UBS AM, an estimated $1.98M sold.

Based on aggregated 13F filings for Q3 2023.